Safety and Efficacy of APD356 in the Treatment of Obesity
Phase 2
Completed
- Conditions
- Obesity
- First Posted Date
- 2005-03-02
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT00104507
- Locations
- 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy
Phase 2
Completed
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- Drug: E7389 28 Day CycleDrug: E7389 21 Day Cycle
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT00100932
A Study of E7389 in Advanced/Metastatic Breast Cancer Patients
- First Posted Date
- 2004-11-30
- Last Posted Date
- 2013-04-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT00097721
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
Phase 3
Completed
- Conditions
- DementiaAlzheimer's Disease
- First Posted Date
- 2004-11-10
- Last Posted Date
- 2011-04-01
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 229
- Registration Number
- NCT00096473
- Locations
- 🇫🇷
Hôpital Broca-La Rochefoucauld, Paris, France
Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy
Phase 2
Completed
- Conditions
- ImpotenceProstate Cancer
- First Posted Date
- 2004-08-30
- Last Posted Date
- 2008-11-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT00090376
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Henry Ford Health System, Vattikuti Institute for Urology, Detroit, Michigan, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients
Phase 2
Completed
- Conditions
- Breast NeoplasmsMetastases
- First Posted Date
- 2004-03-25
- Last Posted Date
- 2006-10-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT00080197
Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma
Phase 1
Completed
- Conditions
- NeoplasmsLymphoma, Malignant
- First Posted Date
- 2004-03-05
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT00078637
Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer
- First Posted Date
- 2004-01-15
- Last Posted Date
- 2012-12-24
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 158
- Registration Number
- NCT00033735
- Locations
- 🇺🇸
MGI Pharma, Incorporated, Bloomington, Minnesota, United States
Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Cancer
- First Posted Date
- 2003-09-24
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT00069277
- Locations
- 🇺🇸
Cancer Institute Medical Group, Los Angeles, California, United States
🇺🇸Premiere Oncology, Santa Monica, California, United States
Study of E7389 in Patients With Advanced Solid Tumors
- First Posted Date
- 2003-09-24
- Last Posted Date
- 2011-12-20
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT00069264
© Copyright 2025. All Rights Reserved by MedPath